In Part B ( dose finding ) , @ patients were randomised to sirukumab ( @mg q@w , @mg q@w , @mg q@w , or @mg q@w ) through week @ , or placebo through week @ with crossover to sirukumab @mg q@w ( weeks @-@ ) .